Skip to main content

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Engages with Leading IR Consultant to Implement Comprehensive IR Effort

Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility to accelerate oncologic drug discovery and enable drug development, has announced a new partnership. The company is working with LifeSci Advisors to implement a comprehensive IR program. The company anticipates the program will include targeting of and outreach to leading analysts and institutional investors, bank conference targeting, non-deal roadshows, corporate communications, and key opinion leader (“KOL”) events focused on AI and machine learning-assisted drug discovery, among other valuable undertakings. LifeSci Advisors is a leading New York-based investor relations (IR) consultancy serving life-science companies. “Simply put, since assuming the role of CEO last November, I have been blown away by the untapped potential of our assets and capabilities, including our artificial intelligence drug discovery engine, PEDAL(TM), that we can leverage against our extensive biobank of more than 150,000 tumor samples and 200,000 pathology slides to accelerate and derisk drug discovery on behalf of academic institution and drug development partners,” said Predictive Oncology CEO Raymond F. Vennare in the press release. “With the global AI-assisted drug development market currently at $1.1 billion and growing at nearly 30% per year, we are indeed in the right place at the right time. I believe the time is now to aggressively raise awareness of our company among influential life sciences analysts, top-tier institutional health-care investors, and other critical participants in the Wall Street health-care ecosystem.”

To view the full press release, visit

About Predictive Oncology Inc.

Predictive Oncology, a science-driven company on the leading edge of oncology drug discovery, offers an unrivaled suite of solutions for the biopharma industry. Through the integration of scientific rigor and machine learning, the company has developed the ability to advance molecules into medicine more confidently by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the world’s largest privately held biobank of more than 150,000 tumor samples. Predictive Oncology’s solutions additionally include tumor models, biologics development, formulation design, a GMP facility, a CLIA laboratory and substantial scientific domain expertise. For more information about the company, please visit

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office

InvestorWire is part of the InvestorBrandNetwork

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.